| Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. | |
| | |
MedLine Citation:
|
PMID: 21080340 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Lenalidomide and azacitidine are active in MDS patients, and may complement each other by targeting the bone marrow microenvironment and the malignant clone. A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging results; however, lenalidomide’s contribution was unclear. In this study, 18 higher-risk MDS patients were treated with the combination for seven cycles, after which lenalidomide was discontinued in eight patients who achieved a complete response, with azacitidine monotherapy continuing until disease progression. We report on three patients who relapsed on monotherapy with excess blasts at 12, 19, and 24 months, in whom lenalidomide was then resumed in combination with azacitidine. Each patient, one with normal cytogenetics at relapse; one with a 18 abnormality; and one with del(4q25), recaptured a complete response that was sustained for 5, 7, and 7+ months. We conclude that the addition of lenalidomide to azacitidine provides additional clinical benefit over azacitidine monotherapy. |
| | |
Authors:
|
Mikkael A Sekeres; Christine O'Keefe; Alan F List; Katarina Paulic; Manuel Afable; Ricki Englehaupt; Jaroslaw P Maciejewski |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: American journal of hematology Volume: 86 ISSN: 1096-8652 ISO Abbreviation: Am. J. Hematol. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7610369 Medline TA: Am J Hematol Country: United States |
Other Details:
|
Languages: eng Pagination: 102-3 Citation Subset: IM |
Affiliation:
|
Department of Hematologic Oncology and Blood Disorders, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA. sekerem@ccf.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Grant Support | |
ID/Acronym/Agency:
|
U54RR19397-03/RR/NCRR NIH HHS |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hepcidin in anemia of chronic heart failure.
Next Document: A reappraisal of Gaucher disease-diagnosis and disease management algorithms.